Objective: We aimed to establish the prevalence of human immunodeficiency virus (HIV)-associated malignancies in children attending a care and treatment clinic at Kilimanjaro Christian Medical Centre.

Materials And Methods: This was a retrospective cross-sectional hospital-based study of children who attended an HIV care and treatment clinic between 2006 and 2014. Children 2 months to 17 years of age were eligible for participation. The data on social demographic and clinical characteristics were extracted from the medical record. A multivariate logistic regression model was developed to determine predictors of HIV-associated malignancies.

Results: Medical records from 721 HIV-infected children were reviewed. The median age (interquartile range) at HIV diagnosis was 5.7 (2.0 to 9.4) years. Among them, 34 (4.7%) had HIV-associated malignancies. The most common (n=24, 70.3%) malignancy was the Kaposi sarcoma. Age at HIV diagnosis was significantly associated with HIV-associated malignancies (adjusted odds ratio, 1.2; 95% confidence interval, 1.0-1.3). Among 34 patients with HIV-associated malignancies, 11 (32.4%) died. Seven (20.6%) patients reported complete remission from their malignancies, and outcomes for 6 patients were unknown.

Conclusions: The prevalence of HIV-associated malignancies was high and was associated with late HIV diagnosis. The Kaposi sarcoma was the commonest malignancy. Early HIV diagnosis and treatment in children might reduce HIV-associated malignancies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597337PMC
http://dx.doi.org/10.1097/MPH.0000000000001389DOI Listing

Publication Analysis

Top Keywords

hiv-associated malignancies
28
hiv diagnosis
16
hiv-associated
8
malignancies
8
hiv-infected children
8
kilimanjaro christian
8
christian medical
8
2006 2014
8
care treatment
8
treatment clinic
8

Similar Publications

Objective: The clinical and laboratory characteristics of HHV8-associated Multicentric Castleman Disease (MCD) in people living with HIV (PLWH) overlap with those of Hemophagocytic Lymphohistiocytosis (HLH) disease and indeed the two diagnoses may co-exist. A risk-stratified treatment approach to MCD based on Rituximab immunotherapy for mild cases and chemo-immunotherapy for severe cases has been shown to yield excellent outcomes in PLWH. In contrast, HLH disease, previously known as secondary HLH, has a dismal prognosis even when promptly treated according to guidelines.

View Article and Find Full Text PDF

Hepatic Flare Following Effective Antiretroviral Therapy Is Associated With HBsAg Seroclearance in HBV/HIV-1 Co-Infection.

J Med Virol

December 2024

Guangzhou Medical Research Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.

Little is known about the clinical significance of hepatic flare following effective antiretroviral therapy (ART) on HBsAg seroclearance and prognosis in HBV/HIV co-infection. This observational cohort study recruited HBV/HIV-1 co-infected patients from the China National Free Antiretroviral Treatment Program. We obtained longitudinal information on demographic characteristics, clinical indicators, and treatment outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Combination antiretroviral therapy (ART) has significantly improved the treatment outcomes for patients with HIV-associated non-Hodgkin lymphoma, specifically Burkitt lymphoma and diffuse large B-cell lymphoma, based on a study of 127 patients treated over 17 years.
  • The study found that DA-EPOCH ± R was the most common therapy for HIV-BL, while CHOP± R was used for HIV-DLBCL, with complete response rates of 36% and 44%, respectively.
  • Despite these advancements, challenges remain in treating HIV-related lymphomas in China due to low rates of pre-diagnosis ART, high patient morbidity, and late-stage diagnoses.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!